1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Piprot, C; Cals, L; Chaigneau, L; Demarchi, F; N'Guyen, T; Stein, U; Villanueva, C; Bréau, JL; Chouahnia, AK; Saintigny, P; Boué, F; deSaint-Hilaire, P; Guimont, I; Grossat, N; Valenza, B; Lévy, E; Médioni, J; Delbaldo, C; Grenier, J; Pouessel, D Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, Pierre; Serin, Daniel; Jacquin, Jean-Philippe; Jouannaud, Christelle; Rios, Maria; Abadie-Lacourtoisie, Sophie; Venat-Bouvet, Laurence; Cany, Laurent; Catal... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 938PDNeed for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group. (23rd October 2018) Authors: de la Motte Rouge, T; Derquin, F; Floquet, A; Edeline, J; Lotz, J-P; Alexandre, J; Pautier, P; Ferron, G; Boissier, E; Lefeuvre-Plesse, C; Vegas, H; Patsouris, A; Kalbacher, E; Berton-Rigaud, D; Hardy Bessard, A-C; Lavoué, V; Ray-Coquard, I L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Issue 9 (September 2019) Authors: de Boer, Stephanie M; Powell, Melanie E; Mileshkin, Linda; Katsaros, Dionyssios; Bessette, Paul; Haie-Meder, Christine; Ottevanger, Petronella B; Ledermann, Jonathan A; Khaw, Pearly; D'Amico, Romerai; Fyles, Anthony; Baron, Marie-Helene; Jürgenliemk-Schulz, Ina M; Kitchener, Henry C; Nijman, Hans... Journal: Lancet oncology Issue: Volume 20:Issue 9(2019) Page Start: 1273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EP1225 How the conformity of surgical practice with the national guidelines improved the quality of management of ovarian granulosa cell tumors (GCT)? A TMRG and GINECO group study. (1st November 2019) Authors: Lenck, C; Chopin, N; Gouy, S; Bonsang Kitzis, H; Martinez Gomez, C; Radosevic-Robin, N; Martin, S; Lefeuvre-Plesse, C; Lambaudies, E; Leblanc, E; Guyon, F; Classe, J-M; Ramanah, R; Beurrier, F; Angeles-Fite, M; Pomel, C; Joly, F; De La Motte Rouge, T; Provansal, M; Lesoin, A Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study. (9th March 2019) Authors: Joly, F; Ahmed-Lecheheb, D; Kalbacher, E; Heutte, N; Clarisse, B; Grellard, J M; Gernier, F; Berton-Rigaud, D; Tredan, O; Fabbro, M; Savoye, A M; Kurtz, J E; Alexandre, J; Follana, P; Delecroix, V; Dohollou, N; Roemer-Becuwe, C; De Rauglaudre, G; Lortholary, A; Prulhiere, K Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and dose modification for patients receiving niraparib. (13th August 2018) Authors: Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety and dose modification for patients receiving niraparib. (14th May 2018) Authors: Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗